Go Deep
Rohto Pharmaceutical Co.,Ltd.
Rohto Pharmaceutical Co.,Ltd. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,883 | 19.7 | 1.98 | 0.18 | 1,651.13 |
Rohto Pharmaceutical Co.,Ltd. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 91,624,000,000.0 | 90,654,000,000.0 | 88,814,000,000.0 | 82,293,000,000.0 |
| Net Profit | 10,650,000,000.0 | 5,968,000,000.0 | 10,627,000,000.0 | 5,883,000,000.0 |
| EPS | 47.1 | — | — | — |
Rohto Pharmaceutical Co.,Ltd. Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 343,725,000,000.0 | 308,625,000,000.0 | 270,840,000,000.0 | 238,664,000,000.0 | — |
| Net Profit | 34,247,000,000.0 | 30,841,000,000.0 | 30,936,000,000.0 | 26,377,000,000.0 | — |
| EPS | 151.6 | 135.4 | 135.6 | 115.6 | — |
Rohto Pharmaceutical Co.,Ltd. Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 485,771,000,000.0 | 437,039,000,000.0 | 346,175,000,000.0 | 309,677,000,000.0 | — |
| Total Liabilities | 165,599,000,000.0 | 156,305,000,000.0 | 99,142,000,000.0 | 94,601,000,000.0 | — |
| Total Equity | 301,826,000,000.0 | 263,371,000,000.0 | 246,323,000,000.0 | 209,568,000,000.0 | — |
Rohto Pharmaceutical Co.,Ltd. Assets & Liabilities Breakdown (JPY millions)
What it owns — Mar 2026
Cash & short-term investments 17.9%Receivables 10.8%Inventory 13.5%Fixed assets (tangible) 19.1%Intangible assets 17.3%Long-term investments 11.5%Other assets 9.8%
How it's funded — Mar 2026
Short-term debt 5.1%Long-term debt 5.8%Payables 4.3%Other liabilities 18.9%Shareholders' equity 65.9%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 86,816.0 | 77,161.0 | 89,210.0 | 79,951.0 |
| Receivables | 52,684.0 | 47,129.0 | 44,744.0 | 39,686.0 |
| Inventory | 65,677.0 | 61,580.0 | 46,657.0 | 41,062.0 |
| Fixed assets (tangible) | 93,011.0 | 90,451.0 | 68,607.0 | 66,182.0 |
| Intangible assets | 83,899.0 | 71,233.0 | 9,217.0 | 9,561.0 |
| Long-term investments | 55,904.0 | 46,427.0 | 44,337.0 | 33,637.0 |
| Other assets | 47,780.0 | 43,058.0 | 43,403.0 | 39,598.0 |
| Liabilities & equity | ||||
| Short-term debt | 24,742.0 | 7,035.0 | 5,304.0 | 4,177.0 |
| Long-term debt | 28,188.0 | 43,188.0 | 5,190.0 | 7,516.0 |
| Payables | 20,937.0 | 19,050.0 | 16,991.0 | 16,025.0 |
| Other liabilities | 91,732.0 | 87,032.0 | 71,657.0 | 66,883.0 |
| Shareholders' equity | 320,172.0 | 280,734.0 | 247,033.0 | 215,076.0 |
| Net tangible assets | 217,927.0 | 192,138.0 | 237,106.0 | 200,007.0 |
Rohto Pharmaceutical Co.,Ltd. Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 47,788,000,000.0 | 36,917,000,000.0 | 34,245,000,000.0 | 30,924,000,000.0 | — |
| Investing Activities | -29,780,000,000.0 | -89,170,000,000.0 | -16,317,000,000.0 | -13,176,000,000.0 | — |
| Financing Activities | -11,845,000,000.0 | 35,319,000,000.0 | -13,784,000,000.0 | -16,199,000,000.0 | — |